Stockreport

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer [TheStreet.com]

Inhibrx Biosciences, Inc.  (INBX) 
PDF PR Newswire SAN DIEGO, April 21, 2026 SAN DIEGO April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-sta [Read more]